close
close

Latest Dupixent (dupilumab) and Itepekimab data at ERS highlight scientific innovation and leadership in respiratory disease

Posted on by Vaseline
Latest Dupixent (dupilumab) and Itepekimab data at ERS highlight scientific innovation and leadership in respiratory disease

20 abstracts, including 4 oral presentations, provide novel treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP)

Data from pivotal Phase 3 studies of Dupixent in COPD confirm reduction in exacerbations and improvement in lung function compared to placebo, and provide new assessments of health-related quality of life in patient subgroups

Display

Long
Short

Related Posts